It is estimated that 30% of the human population present decreased plasma levels of MBL owing to genetic mutations. Therefore, a recombinant human form of MBL as a substitution therapy for MBL-deficient people was developed and found to be safe (171) . The substance is currently under clinical investigation for people suffering from multiple myeloma and undergoing high-dose chemotherapy (145, 172, 173) .